Xiaoli Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaoli Liu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Dajin Yuan
Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
2 shared publications Huimin Li
Department of Gastrointestinal Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
2 shared publications- Lei Ding
Department of Gastrointestinal Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
2 shared publications - Binyan Liu
Department of Gastrointestinal Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
1 shared publication - Dexuan Gao
Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250014, China
1 shared publication - Dongbin Bi
Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021, China
1 shared publication
Latest Publications
- Open Access
- 22 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (21) , e48757
Survival prediction of colorectal cancer using 101 machine learning methods based on immune-related genes: A machine learning study
Colorectal cancer (CRC) is characterized by high incidence and mortality rates. Early identification of high-risk CRC patients and timely intervention are crucial for reducing mortality rates. This study aims to develop a prognostic model incorporating immune-related genes using 101 machine learning algorithms. We utilized data from 630 CRC patients in The Cancer Genome Atlas Program database and the Gene Expression Omnibus database as a validation set. We identified immune-related genes from the ImmPort repository and conducted differential gene expression analysis. We developed 101 machine learning models, including random survival forest, elastic net, LASSO, Ridge regression, stepwise Cox, Coxboost, partial least squares regression for Cox, supervised principal component analysis, generalized boosted modeling, and survival support vector machines. The model with the highest mean concordance index was selected as the optimal prognostic model. The Ridge regression model demonstrated the most robust performance with a mean concordance index of 0.67. Patients with higher immune-related gene risk score (IRGRS) had significantly lower survival rates (log-rank test, P < .001). Univariate and multivariate Cox regression analyses confirmed IRGRS as an independent prognostic factor. Nomograms successfully predicted overall survival at 1, 2, and 3 years. IRGRS correlated with immune cell infiltration levels and stromal activity in the tumor microenvironment. High IRGRS scores were associated with higher tumor immune dysfunction and exclusion scores, suggesting potential differences in response to immune checkpoint inhibitors. In addition, high IRGRS patients exhibited greater sensitivity to certain chemotherapy drugs. The IRGRS score is a potent predictor of survival in CRC patients. This study offers a new perspective for CRC prognosis and supports the development of personalized treatment strategies.
- 22 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (21) , e48757
Open AccessSurvival prediction of colorectal cancer using 101 machine learning methods based on immune-related genes: A machine learning study
Colorectal cancer (CRC) is characterized by high incidence and mortality rates. Early identification of high-risk CRC patients and timely intervention are crucial for reducing mortality rates. This study aims to develop a prognostic model incorporating immune-related genes using 101 machine learning algorithms. We utilized data from 630 CRC patients in The Cancer Genome Atlas Program database and the Gene Expression Omnibus database as a validation set. We identified immune-related genes from the ImmPort repository and conducted differential gene expression analysis. We developed 101 machine learning models, including random survival forest, elastic net, LASSO, Ridge regression, stepwise Cox, Coxboost, partial least squares regression for Cox, supervised principal component analysis, generalized boosted modeling, and survival support vector machines. The model with the highest mean concordance index was selected as the optimal prognostic model. The Ridge regression model demonstrated the most robust performance with a mean concordance index of 0.67. Patients with higher immune-related gene risk score (IRGRS) had significantly lower survival rates (log-rank test, P < .001). Univariate and multivariate Cox regression analyses confirmed IRGRS as an independent prognostic factor. Nomograms successfully predicted overall survival at 1, 2, and 3 years. IRGRS correlated with immune cell infiltration levels and stromal activity in the tumor microenvironment. High IRGRS scores were associated with higher tumor immune dysfunction and exclusion scores, suggesting potential differences in response to immune checkpoint inhibitors. In addition, high IRGRS patients exhibited greater sensitivity to certain chemotherapy drugs. The IRGRS score is a potent predictor of survival in CRC patients. This study offers a new perspective for CRC prognosis and supports the development of personalized treatment strategies.
- 13 March 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (9) , 11869-11881
Exploring mechanisms of britannin against colorectal cancer based on experimentally validated network pharmacology
Britannin is an active compound derived from Inula japonica Thunb. that possess a wide range of pharmacological activities. However, the mechanism underlying its influence on colorectal cancer (CRC) is not clear. This study aimed to explore the mechanism of britannin in treating colorectal cancer. We employed network pharmacology and single-cell RNA sequencing to assess the potential mechanism of britannin in CRC therapy. In vivo and in vitro experiments were conducted to confirm the effect of britannin on CRC cells and tumor environment. Network pharmacology analysis identified 36 britannin-related genes associated with CRC. Key signaling pathways, including the PI3K-Akt pathway, PD-L1 expression, and HIF-1 signaling, were implicated in britannin’s anti-CRC effects. CIBERSORT and scRNA-seq analyses revealed that britannin affects tumor cells, macrophages, and endothelial cells, with a particular impact on macrophage polarization. In vitro assays confirmed that britannin suppressed CRC cell proliferation, promoted apoptosis, and inhibited AKT phosphorylation. In vivo, britannin significantly suppressed tumor growth and modulated the tumor microenvironment by inhibiting M1 macrophage polarization. Britannin may inhibit colorectal by directly inhibiting colon cancer cells and modulating macrophage polarization.
- 13 March 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (9) , 11869-11881
Exploring mechanisms of britannin against colorectal cancer based on experimentally validated network pharmacology
Britannin is an active compound derived from Inula japonica Thunb. that possess a wide range of pharmacological activities. However, the mechanism underlying its influence on colorectal cancer (CRC) is not clear. This study aimed to explore the mechanism of britannin in treating colorectal cancer. We employed network pharmacology and single-cell RNA sequencing to assess the potential mechanism of britannin in CRC therapy. In vivo and in vitro experiments were conducted to confirm the effect of britannin on CRC cells and tumor environment. Network pharmacology analysis identified 36 britannin-related genes associated with CRC. Key signaling pathways, including the PI3K-Akt pathway, PD-L1 expression, and HIF-1 signaling, were implicated in britannin’s anti-CRC effects. CIBERSORT and scRNA-seq analyses revealed that britannin affects tumor cells, macrophages, and endothelial cells, with a particular impact on macrophage polarization. In vitro assays confirmed that britannin suppressed CRC cell proliferation, promoted apoptosis, and inhibited AKT phosphorylation. In vivo, britannin significantly suppressed tumor growth and modulated the tumor microenvironment by inhibiting M1 macrophage polarization. Britannin may inhibit colorectal by directly inhibiting colon cancer cells and modulating macrophage polarization.
- 1 November 2019
- Published by Elsevier in Experimental Cell Research
- Vol. 384 (1) , 111558
HADHA overexpression disrupts lipid metabolism and inhibits tumor growth in clear cell renal cell carcinoma
- 1 November 2019
- Published by Elsevier in Experimental Cell Research
- Vol. 384 (1) , 111558
HADHA overexpression disrupts lipid metabolism and inhibits tumor growth in clear cell renal cell carcinoma